
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

August 2017

Commission File Number: 001-38067

Verona Pharma plc

(Exact Name of Registrant as Specified in Its Charter)

3 More London Riverside

London SE1 2RE UK

+44 203 283 4200

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 21, 2017, Verona Pharma plc issued a release notification system announcement in the United Kingdom (the "RNS") disclosing an acquisition by a person discharging managerial responsibilities.

The RNS is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: August 24, 2017

By: /s/ Jan-Anders Karlsson

Name: Jan-Anders Karlsson, Ph.D.

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Release Notification System Announcement of Verona Pharma plc, dated August 21, 2017



Verona Pharma

PDMR Dealing

August 21, 2017, LONDON — Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.

The notification of dealing form can be found below.

For further information, please contact:

Verona Pharma plc Jan-Anders Karlsson, Chief Executive Officer	Tel: +44 (0)20 3283 4200 info@veronapharma.com
N+1 Singer (Nominated Adviser and UK Broker) Aubrey Powell / James White	Tel: +44 (0)20 7496 3000
FTI Consulting (UK Media and Investor enquiries) Simon Conway / Natalie Garland-Collins	Tel: +44 (0)20 3727 1000 veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries) Darcie Robinson	Tel: +1 203-682-8379 Darcie.Robinson@icrinc.com
Stephanie Carrington	Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name	David Ebsworth				
2	Reason for the notification					
a)	Position/status	Non-Executive Chairman				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Verona Pharma plc				
b)	LEI	213800EVI6O6J3TIAL06				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 5 pence each				
	Identification code	GB00BYW2KH80				
b)	Nature of the transaction	David Ebsworth purchased 8,130 Ordinary Shares				
c)	Price(s) and volume(s)	<table> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>122.5 pence per Ordinary Share</td> <td>8,130 Ordinary Shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	122.5 pence per Ordinary Share	8,130 Ordinary Shares
Price(s)	Volume(s)					
122.5 pence per Ordinary Share	8,130 Ordinary Shares					
d)	Aggregated information	N/A				
	· Aggregated volume					
	· Price					
e)	Date of the transaction	17 August 2017				
f)	Place of the transaction	London Stock Exchange, AIM				

